Evofem Biosciences Stock Book Value Per Share
Evofem Biosciences fundamentals help investors to digest information that contributes to Evofem Biosciences' financial success or failures. It also enables traders to predict the movement of Evofem OTC Stock. The fundamental analysis module provides a way to measure Evofem Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evofem Biosciences otc stock.
Evofem |
Evofem Biosciences OTC Stock Book Value Per Share Analysis
Evofem Biosciences' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Evofem Biosciences Book Value Per Share | (0.77) X |
Most of Evofem Biosciences' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Evofem Biosciences is about -0.765 times. This is 55.0% lower than that of the Pharmaceuticals sector and 99.69% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.04% higher than that of the company.
Evofem Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in book value per share category among its peers.
Evofem Fundamentals
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 8.24 M | ||||
| Gross Profit | 4.19 M | ||||
| EBITDA | (204.14 M) | ||||
| Net Income | (205.19 M) | ||||
| Cash And Equivalents | 19.89 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 125.74 M | ||||
| Debt To Equity | 8.72 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (146.67 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (19.01) X | ||||
| Target Price | 2.9 | ||||
| Number Of Employees | 119 | ||||
| Beta | -1.25 | ||||
| Market Capitalization | 6.41 M | ||||
| Total Asset | 42.51 M | ||||
| Retained Earnings | (526.68 M) | ||||
| Working Capital | 3.78 M | ||||
| Current Asset | 16.39 M | ||||
| Current Liabilities | 12.61 M | ||||
| Z Score | -30.0 | ||||
| Net Asset | 42.51 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |